Dexmedetomidine-ketamine Versus Propofol-ketamine for Sedation During Endoscopy in Hepatic Patients

Anesthesia; Reaction Clinical Trial

Official title:

Dexmedetomidine-ketamine Versus Propofol-ketamine for Sedation During Upper Gastro-intestinal Endoscopy in Hepatic Patients (a Comparative Randomized Study)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04906772
• Other study ID #: FAMSU R 21
• Status: Completed
• Phase: Phase 4
• Start date: February 3, 2021
• Est. completion date: September 30, 2021

Study information

• Verified date: January 2024
• Source: Ain Shams University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

We aim to compare the response to ketamine/dexmedetomidine and ketamine/propofol combinations used in hepatic patients with child-Pugh classification (class A), and early (class B) undergoing UGIE.

Description:

70 Patients will be randomly allocated into two groups; Group (KD): Ketamine/dexmedetomidine (35 patients), will receive IV ketamine 0.25mg/kg and dexmedetomidine1µg/kg over 10 min as loading followed by dexmedetomidine infusion with a rate of 0.5µg/kg/hr and Group (KP): ketamine/propofol (35 patients) will receive IV ketamine 0.25 mg/kg loading and propofol 1 mg/kg over 10 min followed by propofol infusion with a rate of 0.5 mg/kg/hr as a control group.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: September 30, 2021
• Est. primary completion date: July 13, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• hepatic patients with child-Pugh classification (class A), and (class B)

• American Society of Anesthesiologists physical status II, III

• aged 18 to 60 years

• scheduled for elective Upper gastro-intestinal endoscopy.

Exclusion Criteria:

• emergency gastro-intestinal endoscopy.

• patients with severe hepatic disorder (Child C) ,

• chronic neuro-psychiatric disorder,

• history of neuro-psychiatric drug intake,

• severe cardiovascular diseases,

• pregnancy,

• history of drug abuse, and

• history of allergy to any of the used drugs in the study

Related Conditions & MeSH terms

• Anesthesia; Reaction

Intervention

Drug:
• Dexmedetomidine
participants received loading of ketamine 1 mg/kg and dexmedetomidine 1µg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr ketamine and 0.25µg/kg/hr dexmedetomidine throughout the procedure.
• Propofol
participants received loading of ketamine 1 mg/kg and propofol 1mg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr propofol and 0.25µg/kg/hr dexmedetomidine throughout the procedure.

Locations

Country	Name	City	State
Egypt	Faculty of medicine, Ain-Shams university	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Tamer Nabil Abdelrahman

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	induction time	Time to reach target Ramsay Sedation Score = 3	after 5 minutes from the start of drug infusion till target Ramsay Sedation Score = 3 is reached
Primary	Recovery time	time from the stoppage of drug infusion at the end of the procedure till spontaneous eye opening	after 10 minutes from the stoppage of drug infusion at the end of the procedure till spontaneous eye opening